{"news_desk": "Business", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By KATIE THOMAS", "person": [{"rank": 1, "role": "reported", "firstname": "Katie", "organization": "", "lastname": "THOMAS"}]}, "abstract": "Giant drug maker Johnson & Johnson is tapping renowned bioethicist Arthur L Caplan to form panel to evaluate requests by critically ill patients for access to potentially lifesaving, experimental medicines prior to their approval; issue is fraught with emotion and raises basic ethical questions about fairness and equal access to care; move by Johnson & Johnson could prompt other drug makers to follow suit.", "type_of_material": "News", "word_count": "1668", "lead_paragraph": "Johnson & Johnson named the bioethicist Arthur L. Caplan to create a panel to decide on patients\u2019 requests for lifesaving medicines before they are approved.", "pub_date": "2015-05-07T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Company Creates Bioethics Panel on Trial Drugs", "print_headline": "Company Creates Panel for Access to Trial Drugs"}, "snippet": "Johnson & Johnson named the bioethicist Arthur L. Caplan to create a panel to decide on patients\u2019 requests for lifesaving medicines before they are approved.", "multimedia": [{"height": 126, "url": "images/2015/05/07/business/Ethics/Ethics-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/05/07/business/Ethics/Ethics-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 936, "url": "images/2015/05/07/business/Ethics/Ethics-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "936", "xlarge": "images/2015/05/07/business/Ethics/Ethics-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/05/07/business/Ethics/Ethics-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/05/07/business/Ethics/Ethics-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/05/07/business/company-creates-bioethics-panel-on-trial-drugs.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Johnson & Johnson", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Caplan, Arthur L", "name": "persons"}, {"rank": "3", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "New York University Langone Medical Center", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Merck & Company Inc", "name": "organizations"}, {"rank": "6", "is_major": "N", "value": "Chimerix Inc", "name": "organizations"}, {"rank": "7", "is_major": "N", "value": "Ethics and Official Misconduct", "name": "subject"}], "blog": [], "_id": "554ae38d38f0d85a64346934", "source": "The New York Times"}